Bruce Polsky Biography and Net Worth

Director of Atea Pharmaceuticals

Bruce Polsky currently works at NYU Winthrop Hospital, as Professor & Chairman-Medicine from 2015, NYU Langone Hospitals, as Chairman-Medicine Department from 2015, Atea Pharmaceuticals, Inc., as Independent Director from 2014, and Nyu Long Island School of Medicine, as Professor & Associate Dean from 2019. Dr. Polsky also formerly worked at Mount Sinai West, as Chairman-Medicine & Infectious Diseases from 2009 to 2015, Vision-Sciences, Inc., as Independent Director from 2011 to 2014, Stony Brook University School of Medicine, as Professor from 2017 to 2019, ExlService Holdings, Inc., as Vice President-Strategic Account Management, and Icahn School of Medicine at Mount Sinai, as Professor-Medicine & Pathology from 1998 to 2015.

Dr. Polsky received his doctorate degree from Wayne State University (Michigan) and undergraduate degree from the University of Michigan.

What is Bruce Polsky's net worth?: The estimated net worth of Bruce Polsky is at least $202.72 thousand as of June 20th, 2024. Polsky owns 65,606 shares of Atea Pharmaceuticals stock worth more than $202,723 as of December 5th. This net worth evaluation does not reflect any other assets that Polsky may own. Learn More about Bruce Polsky's net worth.
How do I contact Bruce Polsky?: The corporate mailing address for Polsky and other Atea Pharmaceuticals executives is , , . Atea Pharmaceuticals can also be reached via phone at 857-284-8891 and via email at [email protected]. Learn More on Bruce Polsky's contact information.
Has Bruce Polsky been buying or selling shares of Atea Pharmaceuticals?: Bruce Polsky has not been actively trading shares of Atea Pharmaceuticals in the last ninety days. Most recently, Bruce Polsky sold 17,544 shares of the business's stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $3.49, for a transaction totalling $61,228.56. Following the completion of the sale, the director now directly owns 65,606 shares of the company's stock, valued at $228,964.94. Learn More on Bruce Polsky's trading history.
Who are Atea Pharmaceuticals' active insiders?: Atea Pharmaceuticals' insider roster includes Franklin Berger (Director), Andrea Corcoran (Insider), Wayne Foster (CAO), Polly Murphy (Director), Bruce Polsky (Director), and Jean-Pierre Sommadossi (CEO). Learn More on Atea Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Atea Pharmaceuticals?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 359,606 shares worth more than $1,024,877.10. The most recent insider tranaction occured on December, 10th when Director Franklin M Berger sold 359,606 shares worth more than $1,024,877.10. Insiders at Atea Pharmaceuticals own 18.1% of the company. Learn More about insider trades at Atea Pharmaceuticals.
Information on this page was last updated on 12/10/2024.

Bruce Polsky Insider Trading History at Atea Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/20/2024	Sell	17,544	$3.49	$61,228.56	65,606

Bruce Polsky Buying and Selling Activity at Atea Pharmaceuticals

Atea Pharmaceuticals Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $3.09

$3.03

$3.13

50 Day Range

MA: $3.12

$2.82

$3.50

2 Week Range

Now: $3.09

$2.45

$4.02

Volume

497,950 shs

Average Volume

411,257 shs

Market Capitalization

$241.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16